Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Operating Expenses (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Operating Expenses for 6 consecutive years, with $15.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses fell 38.02% year-over-year to $15.2 million, compared with a TTM value of $83.1 million through Sep 2025, up 3.15%, and an annual FY2024 reading of $84.1 million, down 0.71% over the prior year.
  • Operating Expenses was $15.2 million for Q3 2025 at Barinthus Biotherapeutics, down from $23.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $31.6 million in Q4 2022 and bottomed at -$445000.0 in Q3 2022.
  • Average Operating Expenses over 5 years is $17.0 million, with a median of $17.1 million recorded in 2024.
  • The sharpest move saw Operating Expenses tumbled 108.01% in 2022, then surged 3719.1% in 2023.
  • Year by year, Operating Expenses stood at $16.7 million in 2021, then soared by 89.3% to $31.6 million in 2022, then tumbled by 36.65% to $20.0 million in 2023, then rose by 17.94% to $23.6 million in 2024, then plummeted by 35.43% to $15.2 million in 2025.
  • Business Quant data shows Operating Expenses for BRNS at $15.2 million in Q3 2025, $23.3 million in Q2 2025, and $20.9 million in Q1 2025.